A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

@article{Schold2000API,
  title={A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.},
  author={S. Clifford Schold and John G. Kuhn and Susan M. Chang and M E Bosik and Hillary Robins and Minesh P Mehta and Alexander M. Spence and Debra L. Fulton and Karen L. Fink and Michael D. Prados},
  journal={Neuro-oncology},
  year={2000},
  volume={2 1},
  pages={
          34-9
        }
}
The North American Brain Tumor Consortium conducted a phase I trial of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide. Eligibility included a patient with a cancer type that was considered refractory to standard therapy. Prior nitrosourea treatments were not permitted. There were parallel dose escalations in two treatment schedules. Forty-five patients were enrolled during an 18-month period. The maximum tolerated doses (MTDs) when temozolomide followed BCNU (Arm A… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

Similar Papers

Loading similar papers…